Amedisys, Inc. (AMED) DCF Valuation

Amedisys, Inc. (AMED) DCF Valuation
  • ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • ✓ Professional Design: Trusted, Industry-Standard Templates
  • ✓ Pre-Built For Quick And Efficient Use
  • ✓ No Expertise Is Needed; Easy To Follow

Amedisys, Inc. (AMED) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Discover the true value of Amedisys, Inc. (AMED) with our advanced DCF Calculator! Adjust key assumptions, explore various scenarios, and evaluate how changes affect Amedisys, Inc. (AMED) valuation – all within one convenient Excel template.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 1,955.6 2,071.5 2,214.1 2,223.2 2,236.4 2,313.6 2,393.5 2,476.2 2,561.7 2,650.1
Revenue Growth, % 0 5.93 6.88 0.41041 0.59297 3.45 3.45 3.45 3.45 3.45
EBITDA 203.4 250.7 320.7 207.4 216.9 259.2 268.1 277.4 287.0 296.9
EBITDA, % 10.4 12.1 14.48 9.33 9.7 11.2 11.2 11.2 11.2 11.2
Depreciation 18.4 28.8 30.9 24.9 23.8 27.4 28.3 29.3 30.3 31.4
Depreciation, % 0.9423 1.39 1.4 1.12 1.07 1.18 1.18 1.18 1.18 1.18
EBIT 184.9 221.9 289.8 182.5 193.1 231.8 239.8 248.1 256.6 265.5
EBIT, % 9.46 10.71 13.09 8.21 8.63 10.02 10.02 10.02 10.02 10.02
Total Cash 30.3 81.8 42.7 40.5 126.5 69.0 71.3 73.8 76.4 79.0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 237.6 255.1 275.0 296.8 313.4
Account Receivables, % 12.15 12.32 12.42 13.35 14.01
Inventories 74.4 11.8 13.4 25.2 .0 28.3 29.3 30.3 31.3 32.4
Inventories, % 3.81 0.56799 0.60661 1.13 0 1.22 1.22 1.22 1.22 1.22
Accounts Payable 31.3 42.7 38.2 43.7 28.2 39.9 41.2 42.7 44.1 45.7
Accounts Payable, % 1.6 2.06 1.73 1.97 1.26 1.72 1.72 1.72 1.72 1.72
Capital Expenditure -7.9 -5.3 -6.7 -7.2 -12.7 -8.6 -8.9 -9.2 -9.5 -9.8
Capital Expenditure, % -0.40335 -0.2574 -0.30355 -0.32453 -0.56846 -0.37146 -0.37146 -0.37146 -0.37146 -0.37146
Tax Rate, % 124.6 124.6 124.6 124.6 124.6 124.6 124.6 124.6 124.6 124.6
EBITAT 137.6 193.2 216.2 135.1 -47.5 143.8 148.7 153.9 159.2 164.7
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -132.6 273.2 214.4 124.7 -43.2 162.0 158.3 163.8 169.4 175.3
WACC, % 7.66 7.78 7.66 7.66 6.98 7.55 7.55 7.55 7.55 7.55
PV UFCF
SUM PV UFCF 667.6
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 179
Terminal Value 3,222
Present Terminal Value 2,239
Enterprise Value 2,907
Net Debt 361
Equity Value 2,546
Diluted Shares Outstanding, MM 33
Equity Value Per Share 78.11

What You Will Receive

  • Pre-Filled Financial Model: Amedisys, Inc.'s (AMED) actual data enables accurate DCF valuation.
  • Comprehensive Forecast Control: Modify revenue growth, profit margins, WACC, and other crucial drivers.
  • Real-Time Calculations: Automatic updates provide immediate results as you adjust inputs.
  • Professional-Grade Template: A polished Excel file crafted for top-tier valuation.
  • Flexible and Reusable: Designed for adaptability, allowing repeated application for in-depth forecasts.

Key Features

  • Comprehensive DCF Calculator: Provides detailed unlevered and levered DCF valuation models tailored for Amedisys, Inc. (AMED).
  • WACC Calculator: Pre-configured Weighted Average Cost of Capital sheet with adjustable inputs specific to Amedisys, Inc. (AMED).
  • Customizable Forecast Assumptions: Adjust growth rates, capital expenditures, and discount rates to fit Amedisys, Inc. (AMED) projections.
  • Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios relevant to Amedisys, Inc. (AMED).
  • Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for streamlined analysis of Amedisys, Inc. (AMED).

How It Works

  • Download: Obtain the pre-configured Excel file containing Amedisys, Inc.'s (AMED) financial data.
  • Customize: Modify projections, such as revenue growth, EBITDA %, and WACC to fit your analysis.
  • Update Automatically: The intrinsic value and NPV calculations refresh in real-time as you make changes.
  • Test Scenarios: Generate various forecasts and evaluate results side by side effortlessly.
  • Make Decisions: Leverage the valuation findings to inform your investment approach.

Why Choose This Calculator for Amedisys, Inc. (AMED)?

  • Designed for Experts: A sophisticated tool utilized by financial analysts, CFOs, and industry consultants.
  • Accurate Data: Amedisys’s historical and projected financials are preloaded for precision.
  • Forecast Scenarios: Effortlessly simulate various forecasts and assumptions.
  • Comprehensive Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
  • User-Friendly: Step-by-step guidance ensures a smooth experience.

Who Should Use This Product?

  • Individual Investors: Make informed decisions about buying or selling Amedisys, Inc. (AMED) stock.
  • Financial Analysts: Streamline valuation processes with ready-to-use financial models for Amedisys, Inc. (AMED).
  • Consultants: Deliver professional valuation insights on Amedisys, Inc. (AMED) to clients quickly and accurately.
  • Business Owners: Understand how healthcare companies like Amedisys, Inc. (AMED) are valued to guide your own strategy.
  • Finance Students: Learn valuation techniques using real-world data and scenarios related to Amedisys, Inc. (AMED).

What the Template Contains

  • Preloaded AMED Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
  • DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
  • Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
  • Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
  • Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
  • Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.

No products were found matching.